CL097 ( —— )

产品货号. M28181 CAS No. 1026249-18-2

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

拼团产品询价大包装询价加入购物车

产品名称

CL097
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production.
产品描述

CL097 is an effective agonist of TLR7 and TLR8. CL097 induces pro-inflammatory cytokines in macrophages and NADPH oxidase priming, thereby increasing the fMLF-stimulated ROS production.(In Vitro):CL097 (0, 0.5, 2.5, 5, and 10 μg/mL) induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils. CL097 (0.1 μM) induces activation of NF-κB in TLR7-transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells.(In Vivo):in NOD mice, CL097 (5 mg/kg, s.c.) causes a modest specific lysis of the target peptide (～25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone.
同义词

——
通路

Immunology/Inflammation
靶点

ROS
受体

5-LOX
研究领域

——
适应症

——

1.Shang E, et al. Development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors. Bioorg Med Chem. 2014 Apr 15;22(8):2396-402.

计算器

产品手册

关联产品

Lycopene

Extracted from Papaya fruit, marigold flower petals;Store the product in sealed, cool and dry condition.
Ophiopogonin D(b)

Ophiopogonin D(OPD) significantly inhibited the in vitro and in vivo growth of prostate cells via RIPK1 OPD may be developed as a potential anti-prostate cancer agent.
DS-6051b

DS-6051b is a new-generation selective inhibitor of ROS1/NTRK including ROS1,NTRK1,NTRK2 and NTRK3 with IC50 of 0.207 nM,0.622 nM,2.28 nM and 0.980 nM, respectively.DS-6051b inhibited the growth of the ROS1 fusion-positive HCC78 cancer cell line and the CD74-ROS1 overexpressed Ba/F3 cells.